A bone-bonding bioactive material implant in the head and neck: bioglass.

M. Karlan,L. Hench,M. Madden,M. Ogino

Abstract:

What problem does this paper attempt to address?

The Effects of Different Doses of Alfentanil and Dexmedetomidine on Prevention of Emergence Agitation in Pediatric Tonsillectomy and Adenoidectomy Surgery

Yan-zhuo Zhang,Xiong-li Wei,Bin Tang,Yuan-yuan Qin,Min Ou,Xiao-hong Jiang,Yu-feng Tan,Mao-ying Ye

DOI: https://doi.org/10.3389/fphar.2022.648802

IF: 5.6

2022-02-02

Frontiers in Pharmacology

Abstract:Background: Emergence agitation (EA) is a common problem often observed in children after sevoflurane anesthesia, which can be prevented by dexmedetomidine and alfentanil. This study aims to compare the effectiveness of dexmedetomidine alone and with different doses of alfentanil in preventing EA in children under sevoflurane anesthesia. Materials and Methods: In a double-blind trial, 80 children (ASA I or II, 3–7 years old) undergoing tonsillectomy alone and adenotonsillectomy with sevoflurane anesthesia were randomly assigned into four groups: the control group, dexmedetomidine (DEX) group, dexmedetomidine plus 10 μg/kg alfentanil group (DEX + Alf1), and dexmedetomidine plus 20 μg/kg alfentanil group (DEX + ALf2). The incidence of EA was assessed with the Aono’s scale, and the severity of EA was evaluated with the Pediatric Anesthesia Emergence Delirium (PAED) scale. The time of tracheal extubation and time of wake were recorded. Postoperative pain and complications such as nausea and vomiting, cough, laryngospasm, and bradycardia were recorded. Results: The incidence of EA was 50% in the control group, 25% in the DEX group, and 5% in the DEX + Alf1 group, and it never happened in the DEX + Alf2 group. The Aono’s scale, the PAED scale, and the FLACC scale in the control group and the DEX group were significantly more than those in the DEX + Alf1 group and the DEX + Alf2 group after the tracheal extubation ( p < 0.05). The time of tracheal extubation of the control group and the DEX group were significantly shorter than those in the DEX + Alf1 group and the DEX + Alf2 group ( p < 0.05). The awakening time of the DEX + Alf2 group is significantly longer than those in other groups ( p < 0.05). The case of postoperative nausea and vomiting in the DEX + Alf1 group was fewer than those in the other groups ( p < 0.05). And, the cases of cough and laryngospasm and bronchospasm in the DEX + Alf1 group and the DEX + Alf2 group were significantly less than those in the control group and the DEX group after the tracheal extubation ( p < 0.05). Conclusion: The combined administration of alfentanil and dexmedetomidine can reduce EA in children undergoing tonsillectomy alone and adenotonsillectomy with sevoflurane anesthesia. Dexmedetomidine plus 10 μg/kg alfentanil seems to be more appropriate than other dose combinations as it reduced EA and postoperative nausea and vomiting but did not prolong the time to awake.

pharmacology & pharmacy
Effects of a Single Dose Dexmedetomidine on Surgical Field Visibility During Middle Ear Microsurgery: A Randomized Study.

Tingjie Liu,Minju Qin,Wenxian Li,Xia Shen

DOI: https://doi.org/10.1097/MAO.0000000000000996

2016-01-01

Otology & Neurotology

Abstract:Objectives: To investigate whether a single dose of dexmedetomidine (DEX) improves surgical field visibility. Study Design: Randomized, prospective, double-blind study. Setting: Tertiary teaching hospital. Interventions: ASA I or II patients undergoing tympanoplasty with ossiculoplasty were randomly assigned to receive either 0.8 mu g/kg DEX (Group D) or the same volume of saline (Group N) 10 min before anesthesia induction. Main Outcomes: The primary outcome was the visibility of the surgical field rated by surgeons by Boezaart score. The secondary outcomes were consumption of anesthesia, hemodynamic profiles, and subsequent recovery. Results: Boezaart scores for surgical visibility were lower in Group D than in Group N (1.3 +/- 0.8 versus 1.8 +/- 0.9, P = 0.014). Minimum alveolar concentrations of sevoflurane (Group D 1 [0.9/1.1] versus Group N 1 [1/1.2], P = 0.018) and remifentanil consumption (Group D 370 [218/504] mu g versus Group N 583 [300/1028] mu g, P = 0.002) were less in Group D. Except for a transient increase in blood pressure and a decrease in heart rate during DEX infusion, hemodynamic profiles were more stable in Group D than in Group N. More patients needed morphine rescue and presented with postoperative nausea and vomiting in Group N than in Group D (Group D 1 versus Group N 8, P = 0.029). Recovery time was comparable between the two groups (Group D 19 min versus Group N 18 min, P = 0.569). Conclusion: Use of a single dose of DEX resulted in improved surgical visibility, less consumption of anesthesia, and more favorable hemodynamic profile while not delaying recovery time.
Effect of Small Dose of Dexmedetomidine on Development of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gynecologic Surgery

Zhou Yan,Wang Bei,Song Yinan,Wang Dongxin

DOI: https://doi.org/10.3760/cma.j.issn.0254-1416.2016.05.004

2016-01-01

Abstract:Objective To investigate the effect of small dose of dexmedetomidine on the development of postoperative nausea and vomiting in the patients undergoing laparoscopic gynecologic surgery.Methods A total of 207 patients,aged 18-60 yr,of American Society of Anesthesiologists physical status Ⅰ or Ⅱ,scheduled for elective laparoscopic gynecologic surgery under general anesthesia,were randomly divided into either dexmedetomidine group (group D,n=103) or control group (group C,n=104) using a random number table.Before induction of anesthesia,dexmedetomidine 0.1 μg/kg was injected intravenously over 1 min in group D,while the equal volume of normal saline was given instead in group C.At 20 min before the end of surgery,dexmedetomidine 0.04 μg/kg was injected intravenously over 30 s in group D.For the patients requiring patient-controlled analgesia (PCA),PCA solution contained sufentanil 125 μg in 125 ml of normal saline.The PCA pump was set up with a 2 ml bolus dose,a 8 min lockout interval and background infusion at a rate of 1 ml/h.Pethidine was used for PCA after surgery in the patients who did not require PCA.Numeric rating scale scores were maintained ＜4 after surgery.Sufentanil 3 μg was injected intravenously as rescue analgesic in postanaesthesia care unit (PACU).The occurrence of nausea and vomiting was recorded within 0-1 h,1-6 h,6-12 h,and 12-24 h periods after surgery.The occurrence of hypotension and bradycardia during surgery,emergence time,Ramsay sedation score on admission to PACU,requirement for sufentanil as rescue analgesic in PACU,requirement for PCA and antiemetics,and occurrence of somnolence and shivering were recorded.Results Pethidine was not given in the patients who did not require PCA in the two groups.Somnolence and shivering were not found in the two groups.Compared with group C,the incidence of bradycardia was significantly increased,the requirement for antiemetics in PACU and incidence of nausea and vomiting within 1 h after surgery were significantly decreased (P＜0.05),and no significant change was found in the emergence time,Ramsay sedation score,requirement for sufentanil as rescue analgesic,requirement for PCA and total incidence of postsurgical nausea and vomiting in group D (P＞0.05).Conclusion For the patients undergoing laparoscopic gynecologic surgery,small dose of dexmedetomedine can only decrease the development of nausea and vomiting in the early postsurgical period (in PACU),and does not influence the recovery from anesthesia.
Effect of Intranasal Dexmedetomidine or Midazolam for Premedication on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomy and Adenoidectomy

Fangming Shen,Qin Zhang,Yahui Xu,Xinghe Wang,Jiayi Xia,Chao Chen,He Liu,Yueying Zhang

DOI: https://doi.org/10.1001/jamanetworkopen.2022.25473

2022-01-01

JAMA Network Open

Abstract:Importance:Perioperative respiratory adverse events (PRAEs) are the most common complication during pediatric anesthesia, and they may be affected by the administration of preoperative sedatives.Objective:To investigate the effect of intranasal dexmedetomidine or midazolam used for premedication on the occurrence of PRAEs.Design, Setting, and Participants:This single-center, double-blind, randomized clinical trial was conducted among children aged 0 to 12 years undergoing elective tonsillectomy and adenoidectomy from October 2020 to June 2021 at Children's Hospital of Xuzhou Medical University, Xuzhou, China. Data analysis was performed from June to October 2021.Interventions:Children were randomly assigned to 3 groups: the midazolam group received intranasal midazolam (0.1 mg/kg), and the dexmedetomidine group received intranasal dexmedetomidine (2.0 μg/kg) for premedication. The normal saline group received intranasal 0.9% saline for control.Main Outcomes and Measures:The primary outcome was the difference in the incidence of PRAEs among the 3 groups. The secondary outcomes were the frequency of the individual PRAEs, including the incidence of such events during the induction and recovery periods, postoperative emergence delirium, postoperative pain score, sedation success rate, and heart rate values.Results:A total of 384 children (median [IQR] age, 7 [5-10] years; 227 boys [59.1%]) were enrolled and randomized; 373 data sets were available for intention-to-treat analysis (124 children in the midazolam group, 124 children in the dexmedetomidine group, and 125 children in the normal saline group). After the data were adjusted for age, sex, American Society of Anesthesiologists physical status, body mass index, obstructive sleep apnea, upper respiratory tract infection, and passive smoking, children in the midazolam group were more likely to experience PRAEs than those in the normal saline group (70 of 124 children [56.5%] vs 51 of 125 children [40.8%]; adjusted odds ratio [aOR], 1.99; 95% CI, 1.18-3.35), whereas the dexmedetomidine group had a significantly lower PRAEs incidence than the normal saline group (30 of 124 children [24.2%] vs 51 of 125 children [40.8%]; aOR, 0.45; 95% CI, 0.26-0.78). Compared with the dexmedetomidine group, the midazolam group had a higher risk of PRAEs (aOR, 4.44; 95% CI, 2.54-7.76), but no other serious clinical adverse events were observed.Conclusions and Relevance:In this randomized clinical trial, intranasal midazolam used for premedication was associated with increased incidence of PRAEs, whereas premedication with intranasal dexmedetomidine was associated with reduced incidence of PRAEs. Where clinically appropriate, anesthesiologists should consider using intranasal dexmedetomidine for sedation in children undergoing tonsillectomy and adenoidectomy.Trial Registration:Chinese Clinical Trial Register Identifier: ChiCTR2000038359.
Effect of dexmedetomidine on convalescence quality after general anesthesia and postoperative delirium, and on cognitive function in elderly patients undergoing lower limb surgery

Wenbo Wei,Lele Guo

DOI: https://doi.org/10.4314/tjpr.v22i10.22

2023-11-06

Tropical Journal of Pharmaceutical Research

Abstract:Purpose: To investigate the effect of different doses of dexmedetomidine on the quality of postoperative recovery, incidence of postoperative delirium, and cognitive function in elderly patients undergoing lower limb surgery. Methods: A total of 112 patients who received treatment in the Department of Anesthesiology, Affiliated Hospital of Inner Mongolia Medical University, Hothot, China from January 2021 to January 2023 were divided into 3 groups, consisting of low-dose group (35 patients received 0.2 mg/kg), medium-dose group (39 patients received 0.4 mg/kg), and high-dose group (38 patients received 0.6 mg/kg). Parameters including, convalescence quality of general anesthesia, incidence of postoperative delirium, adverse reactions, Mini- mental State Examination (MMSE) scores, sedation effect (Ramsay), analgesia effect (visual analogue scale (VAS)), and stress indices, viz, norepinephrine (NE), epinephrine (E), and cortisol (COR) levels), were evaluated and compared. Results: There was no significant difference in tracheal extubation time, recovery time of spontaneous breathing, calling eye-opening time, or full awakening time among the three groups (p > 0.05). However, MMSE score was significantly higher in low-dose group on days 1 and 3 after surgery (p < 0.05) and VAS scores were significantly higher in low-dose group at 12 and 24 h after recovery compared to other groups (p < 0.05). Ramsay score was significantly higher in high-dose group (p < 0.05). Levels of NE, E, and COR were significantly lower in medium-dose group compared to other groups (p < 0.05). Incidence of adverse reactions were significantly lower in low and medium-dose groups compared to high- dose group (p < 0.05). Conclusion: Medium-dose dexmedetomidine demonstrates favorable sedative and analgesic effects with minimal impact on cognitive function and stress response in elderly patients undergoing lower limb surgery. Furthermore, it does not affect quality of postoperative recovery nor incidence of postoperative delirium. More large-scale, randomized controlled studies are needed to confirm these results.

pharmacology & pharmacy
Effect of Dexmedetomidine on Preventing Agitation and Delirium after Microvascular Free Flap Surgery: A Randomized, Double-Blind, Control Study

Xudong Yang,Zhenzhen Li,Chunyan Gao,Ruichang Liu

DOI: https://doi.org/10.1016/j.joms.2015.01.011

IF: 1.9

2015-01-01

Journal of Oral and Maxillofacial Surgery

Abstract:Purpose: To determine whether dexmedetomidine sedation in the postanesthesia care unit (PACU) could decrease agitation and delirium after free flap surgery.Materials and Methods: Eighty patients were randomly divided into 2 groups. In the experimental group, dexmedetomidine was given at an hourly infusion rate of 0.5 mu g/kg for 1 hour before the operation was completed and continued in the PACU at 0.2 to 0.7 mu g/kg continuously until the next morning. In the control group, normal saline was given during the same periods. Patients in the 2 groups received sufentanil and midazolam for sedation and pain relief when necessary. Agitation was monitored with the Riker Sedation-Agitation Scale in the PACU and delirium was monitored with the Confusion Assessment Method for the Intensive Care Unit for 5 days postoperatively.Results: The overall incidence of agitation was similar between the 2 groups. However, when the influence of patient shiftingwas excluded, the incidence of agitation in the dexmedetomidine group was apparently lower than that in the control group (10.3 vs 30%; P =.029). No difference was found in the occurrence of delirium between the experimental and control groups (5.1 vs 12.5%; P =.432).Conclusion: Dexmedetomidine does not change the overall incidence of agitation after free flap surgery; however, it does decrease agitation after PACU admission. It does not prevent delirium within 5 days postoperatively. (C) 2015 American Association of Oral and Maxillofacial Surgeons
The effect of dexmedetomidine on the incidence of postoperative delirium in critically ill elderly patients

YAO Yue-Qin,WANG Dong-Xin,SHI Cheng-Mei

2012-01-01

Abstract:Objective To evaluate the effect of dexmedetomidine on the incidence of postoperative delirium in critically ill elderly patients.Methods Sixty patients who were 65years or older,having underwent intra-abdominal surgery under combined epidural-general anesthesia were randomly divided into two groups.In treatment group,dexmedetomidine was administrated as an intravenous infusion at the rate of 0.2 μg·kg~(-1)·h~(-1) until the total dose of 200 μg.In the control group,normal saline was given.The visual analogue scores(VAS) of pain at rest and on coughing,VAS score of sleep,as well as the times of demands and the total consumption of PCEA were recorded.The occurrence of postoperative delirium was evaluated regularly until the seventh postoperative day.Results The incidence of hypotension was slightly higher in treatment group than in control group(P<0.05).There were no significant differences between two groups in the VAS pain scores,the total demand times,effective demand times and the total drug consumption of PCEA.The VAS score of sleep was significantly lower in treatment group than in control group on the first postoperative day [(3.48±2.19)vs.(4.67±2.44),P <0.05].There were no significant differences between two groups in postoperative dolirium of nine cases(31.0%) in control group and in 13cases(44.8%) in treatment group.Conclusion In the critically ill elderly patients,continuous intravenous infusion of dexmedetomidine at the rate of 0.2 μg·kg~(-1)·h~(-1) may improve sleep quality,had no significant influence on the analgesic effects of PCEA and on the incidence of postoperative delirium.
Effect of Intraoperative Dexmedetomidine on Recovery of Gastrointestinal Function After Abdominal Surgery in Older Adults

Yao Lu,Pan-Pan Fang,Yong-Qi Yu,Xin-Qi Cheng,Xiao-Mei Feng,Gordon Tin Chun Wong,Mervyn Maze,Xue-Sheng Liu,Yong-Quan Chen,Xian-Wen Hu,Chun-Hui Wang,Xin Wei,Hao Yuan,Xiao-Qiong Xia,Sheng-Bin Wang,Qi Zhang,Jin-Bao Chen,Rui Zhan,Hui Xu,Qing Zhang,Yinguang Fan,,

DOI: https://doi.org/10.1001/jamanetworkopen.2021.28886

2021-10-14

JAMA Network Open

Abstract:Importance: Postoperative ileus is common after abdominal surgery, and small clinical studies have reported that intraoperative administration of dexmedetomidine may be associated with improvements in postoperative gastrointestinal function. However, findings have been inconsistent and study samples have been small. Further examination of the effects of intraoperative dexmedetomidine on postoperative gastrointestinal function is needed.Objective: To evaluate the effects of intraoperative intravenous dexmedetomidine vs placebo on postoperative gastrointestinal function among older patients undergoing abdominal surgery.Design, Setting, and Participants: This multicenter, double-blind, placebo-controlled randomized clinical trial was conducted at the First Affiliated Hospital of Anhui Medical University in Hefei, China (lead site), and 12 other tertiary hospitals in Anhui Province, China. A total of 808 participants aged 60 years or older who were scheduled to receive abdominal surgery with an expected surgical duration of 1 to 6 hours were enrolled. The study was conducted from August 21, 2018, to December 9, 2019.Interventions: Dexmedetomidine infusion (a loading dose of 0.5 μg/kg over 15 minutes followed by a maintenance dose of 0.2 μg/kg per hour) or placebo infusion (normal saline) during surgery.Main Outcomes and Measures: The primary outcome was time to first flatus. Secondary outcomes were postoperative gastrointestinal function measured by the I-FEED (intake, feeling nauseated, emesis, physical examination, and duration of symptoms) scoring system, time to first feces, time to first oral feeding, incidence of delirium, pain scores, sleep quality, postoperative nausea and vomiting, hospital costs, and hospital length of stay.Results: Among 808 patients enrolled, 404 were randomized to receive intraoperative dexmedetomidine, and 404 were randomized to receive placebo. In total, 133 patients (60 in the dexmedetomidine group and 73 in the placebo group) were excluded because of protocol deviations, and 675 patients (344 in the dexmedetomidine group and 331 in the placebo group; mean [SD] age, 70.2 [6.1] years; 445 men [65.9%]) were included in the per-protocol analysis. The dexmedetomidine group had a significantly shorter time to first flatus (median, 65 hours [IQR, 48-78 hours] vs 78 hours [62-93 hours], respectively; P < .001), time to first feces (median, 85 hours [IQR, 68-115 hours] vs 98 hours [IQR, 74-121 hours]; P = .001), and hospital length of stay (median, 13 days [IQR, 10-17 days] vs 15 days [IQR, 11-18 days]; P = .005) than the control group. Postoperative gastrointestinal function (as measured by the I-FEED score) and delirium incidence were similar in the dexmedetomidine and control groups (eg, 248 patients [72.1%] vs 254 patients [76.7%], respectively, had I-FEED scores indicating normal postoperative gastrointestinal function; 18 patients [5.2%] vs 12 patients [3.6%] had delirium on postoperative day 3).Conclusions and Relevance: In this randomized clinical trial, the administration of intraoperative dexmedetomidine reduced the time to first flatus, time to first feces, and length of stay after abdominal surgery. These results suggest that this therapy may be a viable strategy to enhance postoperative recovery of gastrointestinal function among older adults.Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR1800017232.

medicine, general & internal
Effect of Dexmedetomidine on Prevention of Postoperative Nausea and Vomiting in Pediatric Strabismus Surgery: A Randomized Controlled Study

Shuangshuang Li,Tingjie Liu,Junming Xia,Jie Jia,Wenxian Li

DOI: https://doi.org/10.1186/s12886-020-01359-3

IF: 2.086

2020-01-01

BMC Ophthalmology

Abstract:Background : Postoperative nausea and vomiting (PONV) are common side-effects following strabismus surgery. The present study aimed to compare the effects of different doses of dexmedetomidine (DEX) on PONV incidence in pediatric patients undergoing strabismus surgery. Methods : In this prospective randomized double-blinded study, 126 pediatric patients undergoing strabismus surgery were randomized into one of three groups: Placebo group, normal saline; DEX1 group, 0.3 ug/kg dexmedetomidine, and DEX2 group, 0.5 ug/kg dexmedetomidine. Oculocardiac reflex (OCR) events were recorded during surgery. PONV or postoperative vomiting (POV) was recorded for 24 hours in the ward. Pediatric anesthesia emergence delirium (PAED) scale and emergence agitation (EA) scale were recorded in the recovery room. Results : Intraoperative OCR was significantly reduced in DEX2 group (42%) as compared to that of Placebo group (68%) (p=0.0146). During the first 24 hours post-op, the overall incidence of PONV was significantly lower in DEX2 group (10%) than that of Placebo group (32%) (p=0.0142). There was no significant difference in POV among the three groups. PAED or EA scores among the three groups were similar during recovery time. Conclusion : Dexmedetomidine (0.5 ug/kg) reduced OCR and PONV without lengthening extubation time or recovery time in pediatric patients undergoing strabismus surgery.
Effects of dexmedetomidine on surgery for type A acute aortic dissection outcome

Yu-Ting Cheng,Kuang-Tso Lee,Chih-Hsiang Chang,Victor Chien-Chia Wu,Yi-Shin Chan,Dong-Yi Chen,Pao-Hsien Chu,An-Hsun Chou,Kuo-Sheng Liu,Shao-Wei Chen

DOI: https://doi.org/10.1038/s41598-022-06710-w

IF: 4.6

2022-02-17

Scientific Reports

Abstract:Abstract No study has evaluated the effect of dexmedetomidine in patients who received surgery for type A aortic dissection. This is the first study to evaluate the effect of dexmedetomidine in aortic dissection patients. This study was executed using data from the Chang Gung Research Database in Taiwan. The CGRD contains the multi‐institutional standardized electronic medical records from seven Chang Gung Memorial hospitals, the largest medical system in Taiwan. We retrospectively evaluate patients who received surgery for acute type A aortic dissection between January 2014 and December 2018. Overall, 511 patients were included, of whom 104 has received dexmedetomidine infusion in the postoperative period. One-to-two propensity score-matching yielded 86 cases in the dexmedetomidine group and 158 cases in the non-dexmedetomidine group. The in-hospital mortality and composite outcome including all-cause mortality, acute kidney injury, delirium, postoperative atrial fibrillation, and respiratory failure, were considered primary outcomes. The in-hospital mortality and composite outcome were similar between groups. The risk of Acute Kidney Injury Network stage 3 acute kidney injury was significantly lower in the dexmedetomidine group than in the non-dexmedetomidine group (8.1% vs 19.0%; OR, 0.38; 95% CI, 0.17–0.86; p = 0.020. The risk of newly-onset dialysis was also significantly lower in the dexmedetomidine group than in the non-dexmedetomidine group (4.7% vs 13.3%; OR, 0.32; 95% CI, 0.11–0.90; p = 0.031). Post-operative dexmedetomidine infusion significantly reduced the rate of severe acute kidney injury and newly-onset dialysis in patients who received surgery for acute type A aortic dissection.

multidisciplinary sciences
Efficacy of peritonsillar infiltration with dexmedetomidine versus tramadol in comparison to placebo for pain control and sedation after tonsillectomy in pediatric patients: A randomized clinical trial

Hesameddin Modir,Esmail Moshiri,Faezeh Naghavi

DOI: https://doi.org/10.4103/njms.njms_507_21

Abstract:Objective: This article aimed to assess the efficacy of peritonsillar infiltration with dexmedetomidine-ropivacaine versus tramadol-ropivacaine for pain control and sedation after tonsillectomy in pediatric patients. Materials and methods: This double-blind clinical trial recruited 99 eligible children (4-8 years old) undergoing tonsillectomy and assigned to three block-randomized groups, receiving dexmedetomidine-ropivacaine (group A), tramadol-ropivacaine (group B), or placebo-ropivacaine (group C). The vital signs included blood pressure, heart rate, and SaO2 before anesthesia induction, during surgery at regular intervals until 24 h after surgery. The duration of surgery and recovery, complications, and analgesic consumption were recorded and pain scores were measured by Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) and Oucher scales as well as sedation scores by the Wilson sedation scale. Data were analyzed within SPSS 20 at a significance level of 0.05. Results: The lowest pain scores were measured by the CHEOPS scale in the dexmedetomidine-ropivacaine group (P < 0.05). Statistically significant difference was observed in the CHEOPS pain score between the first two groups at 30 min, 1 h, 2 h, and 4 h after surgery (P < 0.01). The differences were revealed in the Oucher pain assessments among all groups from the time of recovery to four postoperative hours (P < 0.05), with the lowest in the dexmedetomidine-ropivacaine group whose sedation score was greater during recovery and 5 min after surgery (P < 0.05). Subjects in tramadol group had six cases of dizziness and nausea, while no side effects were observed in two other groups (P < 0.05). Only seven participants receiving dexmedetomidine required acetaminophen, but 29 in the tramadol group and all in the placebo group demanded to receive acetaminophen (P = 0.001). Conclusion: The authors concluded that dexmedetomidine as an adjuvant to ropivacaine has better performance in local infiltration for intra- and post-tonsillectomy analgesia and postoperative sedation, without any special side effects (like the placebo group), and that it hence is recommended to be used for local infiltration during tonsillectomy.
Dexmedetomidine Effect on Delirium in Elderly Patients Undergoing General Anesthesia: A Protocol for Systematic Review and Meta-Analysis.

Youran Wang,Xinyi Bu,Naiqin Zhao,Shuxia Wang,Xiaoliang Wang,Yali Ge,Honggang Yi

IF: 1.6

2021-01-01

Medicine

Abstract:Delirium is a common postoperative complication. Many studies have found that dexmedetomidine is associated with a reduced incidence of postoperative delirium (POD). This meta-analysis aimed to analyze the effects of dexmedetomidine on POD incidence among elderly patients undergoing general anesthesia.We searched 4 electronic databases (i.e., Pubmed, Embase, Cochrane, and Web of Science) from inception to November 30, 2020, for randomized controlled trials that evaluated the effects of dexmedetomidine in preventing the occurrence of POD in elderly patients (aged ≥60 years). The study protocol was registered in PROSPERO (CRD42020192114).14 studies with 4173 patients showed that dexmedetomidine was significantly associated with a decreased POD incidence among elderly patients (relative risk [RR] = 0.58; 95% confidence interval [CI] = 0.44-0.76). The incidence of POD was significantly reduced in the noncardiac surgery group (RR 0.51; 95% CI 0.37-0.72), when dexmedetomidine was applied during the postoperative period (RR = 0.53; 95% CI = 0.40-0.70), and in patients received low-doses (RR = 0.54; 95% CI = 0.34-0.87) and normal-doses (RR = 0.59; 95% CI = 0.42-0.83). There were no significant differences in POD incidence in the cardiac surgery group (RR = 0.71; 95% CI = 0.45-1.11), and when dexmedetomidine was applied during the intra- (RR = 0.55; 95% CI = 0.29-1.01) or perioperative period (RR = 0.95; 95% CI = 0.64-1.40).Our meta-analysis suggests that dexmedetomidine may significantly reduce POD incidence in elderly noncardiac surgery patients and when applied during the postoperative period, in addition, both low- and normal-doses of dexmedetomidine may reduce POD incidence. However, its use in cardiac surgery patients and during the intra- or perioperative period may have no significant effects on POD incidence.
Effect of Different Doses of Dexmedetomidine on Hemodynamic Response During Laryngoscopy and Tracheal Intubation: A Comparative Prospective Study in GMC Jammu

Dr. Shagufta,Dr. Hitesha Gurtoo

DOI: https://doi.org/10.52403/ijrr.20220878

2022-09-05

International Journal of Research and Review

Abstract:Background: Our study was conceptualised to evaluate and compare the effects of two different doses of dexmedetomidine infusion after single loading dose not only for attenuation of hemodynamic response to laryngoscopy and intubation but also to evaluate the efficacy to reduce post-operative analgesic requirement and its effect on sedation score post-operatively. Methods: This prospective randomized study was conducted in the postgraduate Department of Anaesthesiology and Intensive care, Government Medical College, Jammu after getting approval from Institutional ethical committee. Around 120 patients of either sex ranging in age from 18 to 60 years, belonging to ASA physical status grade 1 and 2, scheduled for elective laparoscopic cholecystectomy under general anaesthesia with endotracheal intubation were enrolled for the study. Results: Dexmedetomidine infusion of 0.5 m g/kg /h after loading dose of 1 mg/kg resulted in stable, steady and smooth reduction in heart rate, and arterial blood pressure with no episode of severe hypotension or other adverse event. The total analgesic requirement in 24 hours in group D1 was 123.83±6.08 mg. The total analgesic requirement in 24 hours in group D2 was 83.72±4.28 mg. The difference between the two groups was statistically significant. Conclusion: Dexmedetomidine infusion of 0.5 mg/kg /h after loading dose of 1 mg/kg successfully maintained hemodynamic stability both intraoperatively and postoperatively. This dose increased the pain free period postoperatively, thus reducing the total analgesic requirement. Dexmedetomidine can, therefore, be considered an anaesthetic adjuvant in laparoscopic cholecystectomy and infusion dose of 0.5mg/kg/h is better than 0.2 mg/kg/ h after loading dose of 1 mg/kg. Keywords: Dexmedetomidine; hemodynamic response; tracheal intubation.
Dexmedetomidine effect on delirium in elderly patients undergoing general anesthesia

Youran Wang,Xinyi Bu,Na Zhao,Shuxia Wang,Xiaoliang Wang,Yali Ge,Honggang Yi

DOI: https://doi.org/10.1097/md.0000000000027782

IF: 1.6

2021-01-01

Medicine

Abstract:Background: Delirium is a common postoperative complication. Many studies have found that dexmedetomidine is associated with a reduced incidence of postoperative delirium (POD). This meta-analysis aimed to analyze the effects of dexmedetomidine on POD incidence among elderly patients undergoing general anesthesia. Methods: We searched 4 electronic databases (i.e., Pubmed, Embase, Cochrane, and Web of Science) from inception to November 30, 2020, for randomized controlled trials that evaluated the effects of dexmedetomidine in preventing the occurrence of POD in elderly patients (aged ≥60 years). The study protocol was registered in PROSPERO (CRD42020192114). Results: 14 studies with 4173 patients showed that dexmedetomidine was significantly associated with a decreased POD incidence among elderly patients (relative risk [RR] = 0.58; 95% confidence interval [CI] = 0.44–0.76). The incidence of POD was significantly reduced in the noncardiac surgery group (RR 0.51; 95% CI 0.37–0.72), when dexmedetomidine was applied during the postoperative period (RR = 0.53; 95% CI = 0.40–0.70), and in patients received low-doses (RR = 0.54; 95% CI = 0.34–0.87) and normal-doses (RR = 0.59; 95% CI = 0.42–0.83). There were no significant differences in POD incidence in the cardiac surgery group (RR = 0.71; 95% CI = 0.45–1.11), and when dexmedetomidine was applied during the intra- (RR = 0.55; 95% CI = 0.29–1.01) or perioperative period (RR = 0.95; 95% CI = 0.64–1.40). Conclusions: Our meta-analysis suggests that dexmedetomidine may significantly reduce POD incidence in elderly noncardiac surgery patients and when applied during the postoperative period, in addition, both low- and normal-doses of dexmedetomidine may reduce POD incidence. However, its use in cardiac surgery patients and during the intra- or perioperative period may have no significant effects on POD incidence.
Effects of dexamethasone on opioid consumption in pediatric tonsillectomy: a systematic review with meta-analysis

Naoko Niimi,Makoto Sumie,Marina Englesakis,Alan Yang,Julia Olsen,Richard Cheng,Jason T Maynes,Paolo Campisi,Jason Hayes,William C K Ng,Kazuyoshi Aoyama

DOI: https://doi.org/10.1007/s12630-024-02817-y

2024-08-27

Abstract:Purpose: Tonsillectomy is one of the most common ambulatory procedures performed in children worldwide, with around 40,000 procedures performed in Canada every year. Although a prior systematic review indicated a clear role for dexamethasone as an analgesic adjunct, the quantity effect on opioid consumption is unknown. In the current systematic review with meta-analysis, we hypothesized that the use of dexamethasone reduces perioperative opioid consumption in pediatric tonsillectomy but does not increase rates of postoperative hemorrhage. Source: We systemically searched MEDLINE, Embase, Cochrane Databases, and Web of Science from inception to 23 April 2024. Randomized controlled trials that compared intravenous dexamethasone to placebo in pediatric tonsillectomy were included in the study. The primary outcome was perioperative opioid consumption, and the secondary outcomes included the incidence of postoperative hemorrhage. We used a random effects meta-analysis to compute the mean difference (MD) or risk ratio (RR) with 95% confidence interval (CI) for each outcome. Principal findings: Of the 1,329 studies identified in the search, we included 16 in the final analysis. Intravenous dexamethasone administration significantly reduced opioid consumption (MD, -0.11 mg·kg-1 oral morphine equivalent; 95% CI, -0.22 to -0.01) without increasing the incidence of readmission (RR, 0.69; 95% CI, 0.28 to 1.67) or reoperation due to postoperative hemorrhage (RR, 3.67; 95% CI, 0.79 to 17.1). Conclusions: Intravenous dexamethasone reduced perioperative opioid consumption in pediatric tonsillectomy without increasing the incidence of postoperative hemorrhage. Study registration: PROSPERO ( CRD42023440949 ); first submitted 4 September 2023.
Anesthetic Effects of Dexmedetomidine Combined with Nalbuphine in Patients Undergoing Laparoscopic Cholecystectomy and its Impact on Nutritional Status

Yue Yang,Li Zhang,Wanjun Yao

DOI: https://doi.org/10.62713/aic.3357

Abstract:Aim: Laparoscopic cholecystectomy (LC) is a common surgical procedure for the removal of the gallbladder. Effective anesthesia is crucial for ensuring patient comfort and safety during LC. Dexmedetomidine, a selective α2-adrenergic agonist, is widely used as an adjunct to anesthesia due to its sedative and analgesic properties. Nalbuphine, a synthetic opioid analgesic, is also employed for pain management during various surgical procedures. This study aimed to determine the anesthesia effects of dexmedetomidine combined with nalbuphine on patients undergoing LC and its impact on their nutritional status. Methods: The clinical records of 100 patients who underwent LC at Wuhan No.1 Hospital between January 2021 and January 2022 were analyzed retrospectively. Forty-six patients who received intravenous dexmedetomidine (0.4 µg/kg) were assigned to the control group, while fifty-four patients who received intravenous nalbuphine (0.2 mg/kg) and dexmedetomidine (0.4 µg/kg) were assigned to the study group. The outcomes compared between the two groups included heart rate (HR), mean arterial pressure (MAP), Riker sedation-agitation scale (RSAS) scores, visual analogue scale (VAS) scores, duration of operation, awakening time from anesthesia, extubation time, adverse reactions, and nutrition-related indicators before and after surgery. Results: There were no significant differences in MAP between the groups at the same time point (p > 0.05). However, at T1 and T3, the study group had significantly lower HR compared to the control group (p < 0.05), with no significant differences in HR at other time points (p > 0.05). The study group exhibited significantly lower RSAS scores compared to the control group (p < 0.01). No significant differences were observed between the groups in terms of duration of operation, awakening time from anesthesia, and extubation time (p > 0.05). At 6 hours post-operation, there were no significant differences in VAS scores between the groups (p > 0.05), but at 12, 24, and 48 hours post-operation, the study group had significantly lower VAS scores compared to the control group (p < 0.0001). No significant inter-group difference was observed in the total incidence of adverse reactions (p = 0.180). Additionally, one week after surgery, the study group exhibited significantly higher levels of albumin, prealbumin, transferrin, and total protein compared to the control group (p < 0.0001). Conclusions: Dexmedetomidine combined with nalbuphine provides a superior anesthetic effect compared to dexmedetomidine alone in patients undergoing LC. This combination effectively controls hemodynamic fluctuations during the recovery period and reduces agitation without affecting the awakening time from anesthesia. These findings suggest that this combination is beneficial and worth promoting.
Perioperative Low Dose Dexmedetomidine and Its Effect on the Visibility of the Surgical Field for Middle Ear Microsurgery: A Randomised Controlled Trial

Jinhong Wu,Yuan Han,Yu Lu,Yan Zhuang,Wenxian Li,Ji'e Jia

DOI: https://doi.org/10.3389/fphar.2022.760916

2022-02-08

Abstract:Background and Purpose: There are many benefits of administering dexmedetomidine perioperatively. The pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous, intranasal and oral dexmedetomidine that was administered before anesthesia were compared in this study, and the effects of dexmedetomidine on the surgical field visibility in tympanoplasty was evaluated. Methods: A single-blind, randomized controlled trial was conducted in a university-affiliated hospital where 45 patients who underwent tympanoplasty under general anesthesia were randomly allocated into three groups. Dexmedetomidine was administered by intravenous infusion at 0.8 μg.kg-1 for 10 min, intranasal instillation at a drop rate of 1 μg.kg-1 and oral intake at 4 μg.kg-1 ten minutes before the induction of anesthesia. The PK and PD of dexmedetomidine after a single low dose administration and its effect on the surgical field in tympanoplasty were analysed. Results: A plasma concentration of dexmedetomidine of 220 pg/ml was achieved immediately after intravenous infusion and at 13.2 and 70.3 min for intranasal and oral administration, respectively. Dexmedetomidine decreased the heart rate (HR) and mean arterial pressure (MAP) in all three groups, although these values remained higher in the oral dexmedetomidine group at all eight time points. Intravenous dexmedetomidine provided the best visualization of the surgical field for opening of the tympanic sinus, 30 min after the start of the infusion (p < 0.05). Intranasal dexmedetomidine provided a significantly better visual field than oral dexmedetomidine for the repair of a tympanic membrane perforation using the fascia temporal muscle (p < 0.05). Conclusion: A single low dose of dexmedetomidine administered intravenously or intranasally could decrease HR and MAP, improve surgical field visibility and be appropriate for deliberate hypotension for surgical procedures of 1-2 h in length. Trial registration: Clinicaltrials.gov identifier: NCT03800641.
Effect of Dexmedetomidine on Anaesthesia Recovery in Patients Undergoing Gynaecological Laparoscopic Surgery

Zhengliang Ma

2011-01-01

Abstract:Objective To evaluate the effect of dexmedetomidine (DEX) on the anaesthesia recovery in patients undergoing gynaecological laparoscopic surgery.Methods Sixty patients scheduled for gynaecological laparoscopic surgery were randomly assigned to three groups (n=20 per group). Group D1 and group D2 received dexmedetomidine 0.4 μg/kg and 0.8 μg/kg infused 30 min before the end of surgery, respectively, while group C received equal volume of normal saline as control. Anesthesia was maintained with combined intravenous-inhalational technique in all groups. HR and MAP were recorded at the following time points: arriving at OR (T0), eyes opening (T1), tracheal extubation (T2), and discharge from PACU (T3); the time for emergence, extubation, and duration in PACU were also recorded. Ramsay sedation scale and Riker agitation scale during emergence and extubation, postoperative adverse events such as vomiting or shivering, and cases requiring analgesic rescue with fentanyl were recorded.Results Extubation time in group D1 and D2 was shorter than that in group C (P0.05). Cases requiring rescue dose of fentanyl in group D2 were fewer than those in group C (P0.05). Ramsay scores were higher and Riker scores were lower in group D2 than in group C and group D1 during emergence (P0.05). Compared with baseline HR at T0, HR was increased at T1 and T2 in group C, and at T2 in group D1 (P0.05), while changes of HR in group D2 had no significant difference. MAP at T2 was increased in group C, and was higher in group C and group D1 than in group D2 (P0.05), while changes of MAP in group D2 had no significance.Conclusion Dexmedetomidine 0.8 μg/kg administered 30 minutes before the end of gynaecological laparoscopic surgery could alleviate postoperative agitation and stabilize hemodynamics without prolonging the recovery time.
Effect of dexmedetomidine on the Montreal Cognitive Assessment in older patients undergoing pulmonary surgery

Tao Liu,Fang-Chao Liu,Yu Xia,Tai-Jun Luo,Fei Wang,Bin Chen,Chun Wang,Guang-Kuo Gao,Wen-Ting Zhai,Wei Liu

DOI: https://doi.org/10.1177/03000605221123680

Abstract:Objective: We investigated the effect of dexmedetomidine anesthesia on postoperative cognitive function after pulmonary surgery. Methods: A blinded, prospective, randomized, placebo-controlled study was performed on 60 patients (age range 65-74 years) undergoing lobectomy by video-assisted thoracoscopic surgery (29 in the dexmedetomidine group; 31 in the placebo group). Dexmedetomidine group patients received dexmedetomidine, and placebo group patients received an equal volume of physiological saline 20 minutes before anesthesia induction. Cognitive function was evaluated using the Montreal Cognitive Assessment 1 day before surgery and on postoperative day (POD)1, POD3, and POD7. The regional cerebral oxygen saturation (rSO2) was monitored continuously by near-infrared spectroscopy before anesthesia. Results: The Montreal Cognitive Assessment score was significantly different between the two groups on POD1 (dexmedetomidine 26.4 ± 0.73 vs. placebo 25.5 ± 0.96) and POD3 (dexmedetomidine 27.1 ± 0.79 vs. placebo 26.6 ± 0.80). Specifically, attention and orientation scores were increased in the dexmedetomidine group on POD1 and POD3. The rSO2 was not significantly different between the dexmedetomidine and placebo groups. Conclusion: Dexmedetomidine given before induction of anesthesia could reduce the risk of postoperative cognitive dysfunction and might not decrease rSO2. Hence, dexmedetomidine could be employed in pulmonary surgical procedures, especially for older patients with a high risk of cognitive dysfunction.
Effects of Systemic Administration of Dexmedetomidine on Intraocular Pressure and Ocular Perfusion Pressure during Laparoscopic Surgery in a Steep Trendelenburg Position: Prospective, Randomized, Double-Blinded Study

Jin Joo,Hyunjung Koh,Kusang Lee,Jaemin Lee

DOI: https://doi.org/10.3346/jkms.2016.31.6.989

Abstract:Increased intraocular pressure (IOP) during surgery is a risk factor for postoperative ophthalmological complications. We assessed the efficacy of systemically infused dexmedetomidine in preventing the increase in IOP caused by a steep Trendelenburg position, and evaluated the influence of underlying hypertension on IOP during surgery. Sixty patients undergoing laparoscopic surgery in a steep Trendelenburg position were included. Patients in the dexmedetomidine group received a 1.0 µg/kg IV loading dose of dexmedetomidine before anesthesia, followed by an infusion of 0.5 µg/kg/hr throughout the operation. Patients in the saline group were infused with the same volume of normal saline. IOP and ocular perfusion pressure (OPP) were measured 16 times pre- and intraoperatively. In the saline group, IOP increased in the steep Trendelenburg position, and was 11.3 mmHg higher at the end of the time at the position compared with the baseline value (before anesthetic induction). This increase in IOP was attenuated in the dexmedetomidine group, for which IOP was only 4.2 mmHg higher (P < 0.001 vs. the saline group). The steep Trendelenburg position was associated with a decrease in OPP; the degree of decrease was comparable for both groups. In intragroup comparisons between patients with underlying hypertension and normotensive patients, the values of IOP at every time point were comparable. Dexmedetomidine infusion attenuated the increase in IOP during laparoscopic surgery in a steep Trendelenburg position, without further decreasing the OPP. Systemic hypertension did not seem to be associated with any additional increase in IOP during surgery. (Registration at the Clinical Research Information Service of Korea National Institute of Health ID: KCT0001482).

A bone-bonding bioactive material implant in the head and neck: bioglass.

The Effects of Different Doses of Alfentanil and Dexmedetomidine on Prevention of Emergence Agitation in Pediatric Tonsillectomy and Adenoidectomy Surgery

Effects of a Single Dose Dexmedetomidine on Surgical Field Visibility During Middle Ear Microsurgery: A Randomized Study.

Effect of Small Dose of Dexmedetomidine on Development of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gynecologic Surgery

Effect of Intranasal Dexmedetomidine or Midazolam for Premedication on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomy and Adenoidectomy

Effect of dexmedetomidine on convalescence quality after general anesthesia and postoperative delirium, and on cognitive function in elderly patients undergoing lower limb surgery

Effect of Dexmedetomidine on Preventing Agitation and Delirium after Microvascular Free Flap Surgery: A Randomized, Double-Blind, Control Study

The effect of dexmedetomidine on the incidence of postoperative delirium in critically ill elderly patients

Effect of Intraoperative Dexmedetomidine on Recovery of Gastrointestinal Function After Abdominal Surgery in Older Adults

Effect of Dexmedetomidine on Prevention of Postoperative Nausea and Vomiting in Pediatric Strabismus Surgery: A Randomized Controlled Study

Effects of dexmedetomidine on surgery for type A acute aortic dissection outcome

Efficacy of peritonsillar infiltration with dexmedetomidine versus tramadol in comparison to placebo for pain control and sedation after tonsillectomy in pediatric patients: A randomized clinical trial

Dexmedetomidine Effect on Delirium in Elderly Patients Undergoing General Anesthesia: A Protocol for Systematic Review and Meta-Analysis.

Effect of Different Doses of Dexmedetomidine on Hemodynamic Response During Laryngoscopy and Tracheal Intubation: A Comparative Prospective Study in GMC Jammu

Dexmedetomidine effect on delirium in elderly patients undergoing general anesthesia

Effects of dexamethasone on opioid consumption in pediatric tonsillectomy: a systematic review with meta-analysis

Anesthetic Effects of Dexmedetomidine Combined with Nalbuphine in Patients Undergoing Laparoscopic Cholecystectomy and its Impact on Nutritional Status

Perioperative Low Dose Dexmedetomidine and Its Effect on the Visibility of the Surgical Field for Middle Ear Microsurgery: A Randomised Controlled Trial

Effect of Dexmedetomidine on Anaesthesia Recovery in Patients Undergoing Gynaecological Laparoscopic Surgery

Effect of dexmedetomidine on the Montreal Cognitive Assessment in older patients undergoing pulmonary surgery

Effects of Systemic Administration of Dexmedetomidine on Intraocular Pressure and Ocular Perfusion Pressure during Laparoscopic Surgery in a Steep Trendelenburg Position: Prospective, Randomized, Double-Blinded Study